We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Is Verapamil In TransRadial Interventions OmittabLe? (VITRIOL)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01402427
First Posted: July 26, 2011
Last Update Posted: June 2, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Istvan Hizoh, MD, PhD, State Health Center, Hungary
July 21, 2011
July 26, 2011
April 17, 2014
June 2, 2014
June 2, 2014
March 2011
August 2011   (Final data collection date for primary outcome measure)
Rate of Access Site Conversions [ Time Frame: Occurrence of access site conversion will be assessed within 1 minute after completion of coronary angiography or intervention. ]
Same as current
Complete list of historical versions of study NCT01402427 on ClinicalTrials.gov Archive Site
  • Rate of Code Breaks [ Time Frame: Occurrence of code breaking will be assessed within 1 minute after completion of coronary angiography or intervention. ]
    Code break: a composite of access site conversion and unplanned use of vasodilators.
  • Rate of Vasodilator Use [ Time Frame: Vasodilator use will be assessed within 1 minute after completion of coronary angiography or intervention. ]
  • Procedural Time [ Time Frame: Procedural time will be assessed within 1 minute after completion of coronary angiography or intervention. ]
  • Fluoroscopic Time [ Time Frame: Fluoroscopic time will be assessed within 1 minute after completion of coronary angiography or intervention. ]
  • Contrast Volume [ Time Frame: The amount of contrast medium will be assessed within 1 minute after completion of coronary angiography or intervention. ]
  • Subjective Pain [ Time Frame: Subjective pain will be assessed within 1 minute after completion of coronary angiography or intervention. ]
    Analysis of the rates of significant pain defined as pain score ≥4 on a semiquantitative scale ranging from 1 to 6.
  • Rate of Code Breaks [ Time Frame: Occurrence of code breaking will be assessed within 1 minute after completion of coronary angiography or intervention. ]
    Code break: a composite of access site conversion and extra use of vasodilators.
  • Rate of Vasodilator Use [ Time Frame: Vasodilator use will be assessed within 1 minute after completion of coronary angiography or intervention. ]
  • Procedural Time [ Time Frame: Procedural time will be assessed within 1 minute after completion of coronary angiography or intervention. ]
  • Fluoroscopic Time [ Time Frame: Fluoroscopic time will be assessed within 1 minute after completion of coronary angiography or intervention. ]
  • Contrast Volume [ Time Frame: The amount of contrast medium will be assessed within 1 minute after completion of coronary angiography or intervention. ]
  • Subjective Pain [ Time Frame: Subjective pain will be assessed within 1 minute after completion of coronary angiography or intervention. ]
    Measured using a semiquantitative scale ranging from 1 to 6.
Not Provided
Not Provided
 
Is Verapamil In TransRadial Interventions OmittabLe?
Omission of Prophylactic Verapamil Use in Transradial Coronary Interventions

Background Verapamil is traditionally applied prophylactically in transradial procedures to prevent radial artery spasm. However, verapamil may have side effects and is contraindicated in some clinical settings.

Methods: During an investigator‐initiated, randomized, double‐blind trial, we evaluate the need for preventive verapamil administration. After vascular access is established, patients receive either 5 mg verapamil (n=297) or placebo (n=294). We compare the rate of access site conversions as primary end point using a superiority margin of 5%. Occurrence of code breaks (composite of conversions and unplanned use of verapamil), overall verapamil use, procedural and fluoroscopic times, contrast volume, and subjective pain are investigated as secondary end points.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
  • Coronary Disease
  • Verapamil Toxicity
  • Drug: Verapamil
    Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.
  • Drug: Placebo
    Intraarterial administration of 10 mL saline.
  • Active Comparator: Verapamil
    Intervention: Drug: Verapamil
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Hizoh I, Majoros Z, Major L, Gulyas Z, Szabo G, Kerecsen G, Korda A, Molnar F, Kiss RG. Need for prophylactic application of verapamil in transradial coronary procedures: a randomized trial. The VITRIOL (is Verapamil In TransRadial Interventions OmittabLe?) trial. J Am Heart Assoc. 2014 Apr 14;3(2):e000588. doi: 10.1161/JAHA.113.000588.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
591
August 2011
August 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • patients undergoing transradial coronary angiography and/or percutaneous coronary intervention
  • successful cannulation of the radial artery

Exclusion Criteria:

  • reduced left ventricular systolic function (LVEF<35%)
  • significant aortic stenosis
  • bradycardia (<50/min.)
  • myocardial infarction complicated by cardiogenic shock and/or high grade AV block
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Hungary
 
 
NCT01402427
SHCCARD-001
No
Not Provided
Not Provided
Istvan Hizoh, MD, PhD, State Health Center, Hungary
State Health Center, Hungary
Not Provided
Principal Investigator: Istvan Hizoh, MD, PhD State Health Center, Budapest, Hungary
Study Chair: Robert Gabor Kiss, MD, PhD State Health Center, Budapest, Hungary
State Health Center, Hungary
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP